Currently, the National Comprehensive Cancer Network (NCCN) and ASCO guidelines recommend chemotherapy combined with trastuzumab as neoadjuvant therapy for early-stage HER2-positive breast cancer, with the aim of reducing the tumour burden and optimizing surgical outcomes (7, 8). This evidence concerns the gene ERBB2 and breast carcinoma.